Navigation Links
Vetter Offers a Sterile Water-for-injection Solution with 5 Years Stability Data

Ravensburg (PRWEB) July 10, 2013

Vetter has broadened its portfolio for lyophilized substances. The contract development and manufacturing organization (CDMO) is now offering its filling service for high-quality sterile water for injection (sWFI) syringes with 5 years of stability data. Vetter’s stability data and bracketing concept allows a longer shelf life for drugs, and high flexibility while defining the filling volume. Vetter can also offer ready-to-submit documents for the sWFI service in Common Technical Document (CTD) format. This can considerably abbreviate the approval process.

Because innovative drugs are becoming increasingly more sensitive to environmental influences, they are often lyophilized to increase their shelf life. In a freeze-dried state, these drugs maintain their bioactivity for longer periods of time. However, before being administered they have to be reconstituted and dissolved in a solvent, after which they are ready for injection. The filling service for syringes with sterile water-for-injection (sWFI) is Vetter’s intelligent solution for safe and simple handling of the reconstitution process. The system contains the exact defined amount of solvent required by the customer in order to produce the required dosage. This helps to assure patients that they will receive the exact amount of substance needed.

Vetter’s filling service for sWFI syringes is an ideal complement to lyophilized drugs in vials and is available in 1.5 ml formats with a volume of 0.5 ml to 1.3 ml, as well as a 3 ml format with a volume of 1.4 ml to 3.0 ml. The syringe features Vetter’s V-OVS® tamper-evident closure, which is designed to give a prefilled syringe system effective protection features. Vetter supports its sWFI filling service with 5 years of stability data and can manufacture batches of up to 120,000 / 140,000 pieces. For the sWFI syringes, Vetter has ICH compliant and ready-to-submit documentation for the USA, Europe, and Japan. Validation and stability data according to USP, Ph.Eur., Ph.J., and ICH guidelines are also available.

“Lyophilized drugs are an international growth segment for CDMO’s,” says Peter Soelkner, Managing Director of Vetter. "An ever greater number of manufacturers are looking for options to enable a safe and simple administration of these drugs. Our filling service for WFI syringes represents a reliable and patient-friendly solution offering our customers high-flexibility due to Vetter’s bracketing concept, and fast time-to-market by using the ready-to-submit documents. In addition to documents for approval in the USA and Europe, we also have all the necessary documentation for Japan available for pharmaceutical and biotech firms, which can considerably abridge the approval process.”

About Vetter:

Vetter is a leading contract development and manufacturing organization (CDMO) that specializes in the aseptic filling of syringes, cartridges and vials. The company has extensive experience with biologics and other complex compounds, including monoclonal antibodies, peptides, interferons and vaccines. Its clientele includes the world’s top 10 pharma/biotech firms and emerging companies alike. A full-service provider, Vetter supports products throughout their lifecycles, from preclinical development through global market supply. Through its U.S. and European facilities, Vetter Development Service provides state-of-the-art support for early-stage products, with seamless transfer at Phase III to Vetter Commercial Manufacturing for large-scale production. The company is the originator of dual-chamber technology, which enables easier, safer lyophilized-drug administration; and is a leader in the use of RABS technology in cleanrooms, which mitigates risk of product contamination during the manufacturing process. Vetter has won numerous awards for innovation and quality, including top prize at the 2012 European Outsourcing Awards for its new high-speed filling line. Headquartered in Ravensburg, Germany, the company employs approximately 3,000 staff across Europe and the United States. For more information about Vetter, visit

Vetter Pharma International GmbH
Oskar Gold
Eywiesenstrasse 5
88212 Ravensburg
Phone: +49 (0)751-3700-3706
Fax: +49 (0)751-3700-7707
E-mail: PRnews(at)vetter-pharma(dot)com

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Fortis Offers Bachelor of Science in Nursing Degree Program to Florida Students
2. Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery
3. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
4. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
5. Big Saver: Molderizer Offers 30% Mold Remediation Products Price Cut
6. Tri-Valley Sedation Dentist Dr. Endre Selmeczy Now Offers High-quality Dental Restorations
7. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
8. Salimetrics Offers New Saliva Collection Aid for Easy Collection of Passive Drool Samples
9. AMRESCO Offers New Prism Protein Marker With Vibrant Colors For Easy Band Identification
10. Dr. Ross Kaplan Offers New State-of-the-Art Wrinkle, Fine Line, and Skin Texture Improvement Treatment
11. Flat lens offers a perfect image
Post Your Comments:
(Date:11/23/2015)... Nov. 24, 2015 Women with a certain type ... face a higher risk of lung cancer than men with ... week at the annual meeting of the Radiological Society of ... --> --> Lung nodules are small ... solid or subsolid based on their appearance on CT. Solid ...
(Date:11/23/2015)... 2015 China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell ... preliminary unaudited financial results for the second quarter and ... 2015. --> --> ... for the second quarter of fiscal 2016 increased by ...
(Date:11/23/2015)... Church, VA (PRWEB) , ... November 23, 2015 , ... ... Ellen McCarthy , former Director, Plans and Programs, National Geospatial Intelligence Agency (NGA), has ... to us with an incredibly distinguished career in the intelligence community and the private ...
(Date:11/23/2015)... and PISCATAWAY, New Jersey ... Cambridge Crystallographic Data Centre (CCDC) announces the ... Structural Database (CSD) and the CSD-System, now complemented ... worldwide: CSD-Discovery to support the discovery of new ... and CSD-Enterprise, the complete set of the CCDC,s ...
Breaking Biology Technology:
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
Breaking Biology News(10 mins):